Mergers & Acquisitions - Biotechnology, Antibiotics and Infectious diseases

Filter

Popular Filters

Synthetic Biologics to acquire clinical-stage C. diff infectious disease program

12-11-2012

USA-based Synthetic Biologics (NYSE: SYN), a developer of synthetic biologics and innovative medicines…

Antibiotics and Infectious diseasesBiotechnologyMergers & AcquisitionsPrev AbRSYN-004Synthetic Biologics

Forest acquires rights to Nabriva antibacterial and option to buy firm

04-06-2012

US drugmaker Forest Laboratories (NYSE: FRX) says it has entered into an agreement with Austrian biotech…

Antibiotics and Infectious diseasesBC-3781BiotechnologyForest LaboratoriesLicensingMergers & AcquisitionsNabriva TherapeuticsPharmaceutical

Back to top